OPC Koustenis, Breiter. General Comments Surrogate for Control Group Benchmark for Minimally Acceptable Values Not a Control Group Driven by Historical.

Slides:



Advertisements
Similar presentations
Bayes rule, priors and maximum a posteriori
Advertisements

Non-randomized studies: Studies with historical controls and the use of Objective Performance Criteria (OPCs) Jeff Cerkvenik Statistics Manager Medtronic,
COMPUTER INTENSIVE AND RE-RANDOMIZATION TESTS IN CLINICAL TRIALS Thomas Hammerstrom, Ph.D. USFDA, Division of Biometrics The opinions expressed are those.
Roseann White Clin/Reg Felllow Abbott Vascular – Cardiac Therapies
Modeling of Data. Basic Bayes theorem Bayes theorem relates the conditional probabilities of two events A, and B: A might be a hypothesis and B might.
Review bootstrap and permutation
Phase II/III Design: Case Study
Shibing Deng Pfizer, Inc. Efficient Outlier Identification in Lung Cancer Study.
A Flexible Two Stage Design in Active Control Non-inferiority Trials Gang Chen, Yong-Cheng Wang, and George Chi † Division of Biometrics I, CDER, FDA Qing.
Bayesian inference of normal distribution
Uncertainty in fall time surrogate Prediction variance vs. data sensitivity – Non-uniform noise – Example Uncertainty in fall time data Bootstrapping.
Week 11 Review: Statistical Model A statistical model for some data is a set of distributions, one of which corresponds to the true unknown distribution.
Bayesian Adaptive Methods
Bayesian inference “Very much lies in the posterior distribution” Bayesian definition of sufficiency: A statistic T (x 1, …, x n ) is sufficient for 
Bayesian Estimation in MARK
Bayesian posterior predictive probability - what do interim analyses mean for decision making? Oscar Della Pasqua & Gijs Santen Clinical Pharmacology Modelling.
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
RELATIVE RISK ESTIMATION IN RANDOMISED CONTROLLED TRIALS: A COMPARISON OF METHODS FOR INDEPENDENT OBSERVATIONS Lisa N Yelland, Amy B Salter, Philip Ryan.
Sample size optimization in BA and BE trials using a Bayesian decision theoretic framework Paul Meyvisch – An Vandebosch BAYES London 13 June 2014.
Bayesian inference Gil McVean, Department of Statistics Monday 17 th November 2008.
Making rating curves - the Bayesian approach. Rating curves – what is wanted? A best estimate of the relationship between stage and discharge at a given.
Assuming normally distributed data! Naïve Bayes Classifier.
Longitudinal Experiments Larry V. Hedges Northwestern University Prepared for the IES Summer Research Training Institute July 28, 2010.
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
USE OF LAPLACE APPROXIMATIONS TO SIGNIFICANTLY IMPROVE THE EFFICIENCY
Using ranking and DCE data to value health states on the QALY scale using conventional and Bayesian methods Theresa Cain.
QMS 6351 Statistics and Research Methods Chapter 7 Sampling and Sampling Distributions Prof. Vera Adamchik.
Bayesian Methods for Benefit/Risk Assessment
Lecture 9: p-value functions and intro to Bayesian thinking Matthew Fox Advanced Epidemiology.
Psy B07 Chapter 1Slide 1 ANALYSIS OF VARIANCE. Psy B07 Chapter 1Slide 2 t-test refresher  In chapter 7 we talked about analyses that could be conducted.
Understanding the Concept of Equivalence and Non-Inferiority Trials CM Gibson, 2000.
PROBABILITY (6MTCOAE205) Chapter 6 Estimation. Confidence Intervals Contents of this chapter: Confidence Intervals for the Population Mean, μ when Population.
1 G Lect 6b G Lecture 6b Generalizing from tests of quantitative variables to tests of categorical variables Testing a hypothesis about a.
Bayesian inference review Objective –estimate unknown parameter  based on observations y. Result is given by probability distribution. Bayesian inference.
Estimating parameters in a statistical model Likelihood and Maximum likelihood estimation Bayesian point estimates Maximum a posteriori point.
Particle Filters for Shape Correspondence Presenter: Jingting Zeng.
Lecture 15: Statistics and Their Distributions, Central Limit Theorem
Nguyen D. Nguyen, John A. Eisman and Tuan V. Nguyen Garvan Institute of Medical Research, Sydney, Australia Indirect comparison of anti-vertebral fracture.
Mixture Models, Monte Carlo, Bayesian Updating and Dynamic Models Mike West Computing Science and Statistics, Vol. 24, pp , 1993.
Therapeutic Equivalence & Active Control Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Maximum Likelihood - "Frequentist" inference x 1,x 2,....,x n ~ iid N( ,  2 ) Joint pdf for the whole random sample Maximum likelihood estimates.
1 OTC-TFM Monograph: Statistical Issues of Study Design and Analyses Thamban Valappil, Ph.D. Mathematical Statistician OPSS/OB/DBIII Nonprescription Drugs.
Center for Radiative Shock Hydrodynamics Fall 2011 Review Assessment of predictive capability Derek Bingham 1.
Week 41 Estimation – Posterior mean An alternative estimate to the posterior mode is the posterior mean. It is given by E(θ | s), whenever it exists. This.
Bayesian Approach For Clinical Trials Mark Chang, Ph.D. Executive Director Biostatistics and Data management AMAG Pharmaceuticals Inc.
Ch15: Decision Theory & Bayesian Inference 15.1: INTRO: We are back to some theoretical statistics: 1.Decision Theory –Make decisions in the presence of.
1 Bayesian Essentials Slides by Peter Rossi and David Madigan.
Bayesian Travel Time Reliability
Contact: Jean-François Michiels, Statistician A bayesian framework for conducting effective bridging between references.
Statistics What is the probability that 7 heads will be observed in 10 tosses of a fair coin? This is a ________ problem. Have probabilities on a fundamental.
Bayes Theorem. Prior Probabilities On way to party, you ask “Has Karl already had too many beers?” Your prior probabilities are 20% yes, 80% no.
Timothy Aman, FCAS MAAA Managing Director, Guy Carpenter Miami Statistical Limitations of Catastrophe Models CAS Limited Attendance Seminar New York, NY.
Spatially Explicit Capture-recapture Models for Density Estimation 5.11 UF-2015.
Hypothesis Testing. Statistical Inference – dealing with parameter and model uncertainty  Confidence Intervals (credible intervals)  Hypothesis Tests.
Bayesian Brain Probabilistic Approaches to Neural Coding 1.1 A Probability Primer Bayesian Brain Probabilistic Approaches to Neural Coding 1.1 A Probability.
Institute of Statistics and Decision Sciences In Defense of a Dissertation Submitted for the Degree of Doctor of Philosophy 26 July 2005 Regression Model.
Ch 1. Introduction Pattern Recognition and Machine Learning, C. M. Bishop, Updated by J.-H. Eom (2 nd round revision) Summarized by K.-I.
Canadian Bioinformatics Workshops
Estimation of Gene-Specific Variance
The Importance of Adequately Powered Studies
Probability Theory and Parameter Estimation I
Regression Analysis Part D Model Building
Statistical Approaches to Support Device Innovation- FDA View
Deputy Director, Division of Biostatistics No Conflict of Interest
FDA/INDUSTRY STATISTICS WORKSHOP: Washington, D. C. Sept
More about Posterior Distributions
CS639: Data Management for Data Science
Subhead Calibri 14pt, White
Mathematical Foundations of BME Reza Shadmehr
A Bayesian Design with Conditional Borrowing of Historical Data in a Rare Disease Setting Peng Sun* July 30, 2019 *Joint work with Ming-Hui Chen, Yiwei.
Presentation transcript:

OPC Koustenis, Breiter

General Comments Surrogate for Control Group Benchmark for Minimally Acceptable Values Not a Control Group Driven by Historical Data Requires Pooling of Different Investigations

(continued) Periodical Re-Evaluation and Updating the OPCs Policy not yet formalized –Specific Guidance on Methodology to Derive an OPC –Is urgently needed

Bayesian Issues in Developing OPC Objective means? –Derived from (conditionally?) exchangeable studies –Non-informative hyper-prior For new Bayesian trials should the OPC be expressed as a (presumably tight) posterior distribution rather than a fixed number? –E.g. logit(opc) ~ normal(?,?), etc

Does OPC Preempt an Informative Prior? An objective informative prior would be derived from some of the same trials used to set the OPC. This could be dealt with by computing the joint posterior distribution of opc and p new. But this would be extremely burdensome to implement for anything but an in- house OPC (Breiter). A non-informative prior might be least burdensome.

Bayesian Endpoints Superiority: –P(p new < opc | New Data) Non-inferiority –P(p new < opc + | New Data) –PP(p new < kopc | New Data)

OPC as an Agreed upon Standard Historical Data + ??? Are evaluated to produce an agreed upon OPC as a fixed number with no uncertainty. Can I used some of these same data to develop an informative prior? Probably yes but needs work. The issue is what claim will be made for a successful device trial.

The prior depends on the Claim Claim: The complication rate (say) of the new device is not larger than (say) the median of comparable devices +. –If the new device is exchangeable with a subset of comparable devices then the correct prior for the new device is the joint distribution of (p new, opc) prior to the new data. –If the new device is not exchangeable with any comparable devices, then a non- informative prior should be used.

(continued) Claim: The complication rate of the new device is not greater than a given number (opc + ). –The prior can be based on device trials that are considered exchangeable with the planned trial (e.g. in house).

Logic Chopping? Not necessarily. Consider –The average male U of IA professor is taller than the average male professor. vs –The average male U of IA professor is taller than 511 How you or I arrived at the 511 is not relevant to the posterior probability.

But perhaps thats a bit disingenuous The regulatory goal is clearly to set an OPC that will not permit the reduction of average safety or efficacy of a class of devices. Of necessity, it has to be related to an estimate of some sort of average. So a claim of superiority or non-inferiority to an opc is clearly made at least indirectly with reference to a control

Would it Make sense to Express the OPC as a PD? If the OPC is derived from a hierarchical analysis of exchangeable device trials it would be possible to compute the predictive distribution of x new. Could inferiority (superiority) be defined as the observed x new being below the 5 th (above the 95 th ) percentile of the predictive distribution?

Poolability Roseann White

Binary Response Setup i = arm (T or C) j = center k = Ss Response variable y ijk ~ bernoulli(p ij ) logit(p Cj ) = j logit(p Tj ) = j + + j Primary: > - Secondary: j s are within clinical tolerance

Specify Secondary Goal ? If the difference between the treatment group varies more than twice the non- inferiority margin [ ] Possible interpretations: –Random CxT interaction: < 2 –Multiple comparisons: max | j – k | < 2

(continued) Modify... Liu et. al... Center j is non-inferior: + j > -k All centers must be non-inferior? ID the inferior centers?

Why Bootstrap Resample? To increase n of Ss in clusters? --- Probably invalid To generate a better approximation of the null sampling distribution? --- OK, but what are the details? Do you combine the two arms and resample? Why not use random-effects Glimmix if you want to stick to frequentist methods.

Bayesian Analysis Ad-hoc pooling is not necessary Can produce the posterior distribution of any function of the parameters. Can use non-informative hyper-priors, so is objective = data driven. Will have the best frequentist operating characteristics (which could be calculated by simulation.)

Bayesian Setup Define j = + j (logit of p in the T arm) ( j, j ) ~ iid N((, ) have near non-informative priors Primary goal: P( | Data) (or -bar) Secondary goal(s): ?? –P( < 2 | Data) (or s –For each (j,j) P(| j – j | < 2 | Data) –For each j P(| j – | < 2 | Data) –For each j P( j > -k | Data)

Bayes Could Use the Original Metric p Cj = 1/(1+exp(- j )) p Tj = 1/(1+exp(- j - j )) p C = 1/(1+exp(- )) p T = 1/(1+exp(- - )) Primary: P(p T – p C > | Data) Secondary: –e.g. P(p Tj – p Cj > k(p T – p C ) | Data)